61 results about "Leptin" patented technology

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The invention discloses a satiety sugar-controlling fat-reducing composition and a preparation method and application thereof, the satiety sugar-controlling fat-reducing composition comprises hydrogel particles, a white kidney bean extract, a mulberry leaf extract, alpha-lipoic acid, L-carnitine, a lotus leaf extract, medium chain triglyceride, polyethylene glycol and sorbitol, and the composition is a tablet. The components are matched with one another to effectively adjust the leptin level, improve appetite, increase energy consumption, adjust the fat metabolism process, reduce fat accumulation, improve fat consumption, inhibit the activity of alpha-amylase, reduce the conversion of carbohydrates into fat, block heat and fat intake, promote gastrointestinal motility and enhance the immunity of the human body. The effects of remarkably reducing the fat content and the body weight are achieved.

The invention relates to a preparation method and application of a medicine-food homologous compound with weight-losing and lipid-lowering effects. According to the present invention, the weight of the obese mouse can be reduced by 23.23% at most, the serum total cholesterol is reduced, the leptin secretion is reduced, AST (aspartate transaminase) and ALT (alanine transaminase) have no significant difference compared to the model mouse, the volume of epididymal fat and inguinal fat cells is reduced, the number of cells in unit area is significantly increased, the fatty liver sample is relieved, the TMEM26 gene expression in the epididymal fat is significantly increased, and the weight of the obese mouse can be significantly reduced; the expression quantity of the UCP1 gene in brown fat is obviously increased. The traditional Chinese medicine composition adopts medicinal and edible substances as raw materials, is widely applicable to people, is more suitable for prevention and treatment of chronic diseases, is safe and effective, and causes little damage to liver and kidney after long-term use.

Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

The present disclosure provides methods of treating congenital generalized lipodystrophy using tirzepatide. The disclosure also provides methods for treating a disease in a patient characterized by leptin and leptin signaling deficiency.

The present invention discloses a tetrahedral framework nucleic acid-triptertium complex and its preparation method and application, and belongs to the field of medical technology. The complex is a complex formed by mixing tetrahedral framework nucleic acid and triptertium, and the molar ratio of the tetrahedral framework nucleic acid and triptertium is 1: (20-25). The tetrahedral framework nucleic acid-triptertium complex of the present invention realizes drug delivery to a variety of target tissues / organs (especially the key target organ-hypothalamus) at the same time, and it itself hardly produces side effects. The complex can significantly reduce the inflammatory level of adipose tissue in obese mice, significantly improve glucose tolerance and insulin resistance in obese mice, significantly increase the energy consumption and heat production level of obese mice, and significantly reduce the blood leptin level of obese mice, and has broad application prospects in the preparation of weight loss drugs and drugs for the prevention of diabetes.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

The invention belongs to the technical field of biological medicines, and particularly relates to a targeted polypeptide and application thereof. It is found that in a mouse obesity model, hypothalamic arcuate nucleus and para-ventricular nucleus overexpression DEC2 can significantly induce leptin resistance and obesity; a key binding region of interaction of DEC2 and STAT3 is further analyzed, and a polypeptide (Tat-DEC2) targeting DEC2 is constructed. In-vitro experiments prove that the Tat-DEC2 polypeptide can effectively improve the leptin reactivity of DEC2 overexpression mouse hypothalamic neurons, and the effect of the Tat-DEC2 polypeptide has time dependence and concentration dependence; in-vivo experiments prove that the Tat-DEC2 polypeptide can significantly improve leptin resistance and play an effective weight reducing role. The polypeptide is used for intervening key molecules caused by leptin resistance, so that the occurrence mechanism of obesity induced by leptin resistance is understood more deeply, and meanwhile, the polypeptide has important significance in developing effective clinical treatment drugs.

The present invention relates to a Korean microbiome-derived Clostridium butyricum strain having anti-obesity efficacy and a use thereof. The strain has an excellent effect of reducing the body weight and adipose tissue weight of experimental animals compared to a control group (strain-untreated) under high-fat diet conditions, has an excellent effect of reducing the content of total cholesterol, triglycerides, low-density lipoprotein (LDL), leptin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum, and has an excellent effect of reducing blood glucose and increasing the content of glucagon-like peptide-1 (GLP-1) in an oral glucose load test, and is thus expected to be effectively used as an ingredient in a composition for preventing, alleviating, or treating obesity and metabolic diseases caused by obesity.

Formulations of HDAC6 inhibitors that traverse the blood brain barrier in the hypothalamus and inhibit HDAC6 in arcuate AgRP neurons in the hypothalamus are effective for causing weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin resistant individuals.

To provide modified or polymer conjugated MetAP2 inhibitors.SOLUTION: The present invention relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.SELECTED DRAWING: Figure 1

Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.

The invention discloses a lipid-lowering and weight-losing composition with homology of medicine and food as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The composition for reducing fat and losing weight comprises the following raw materials in parts by weight: 10-40 parts of lotus leaves, 20-50 parts of haws, 15-45 parts of poria cocos, 5-35 parts of dried orange peel, 60-130 parts of raspberries, 0-15 parts of fingered citron and 0-15 parts of kudzuvine roots. Compared with a model group, the fat-reducing and weight-losing composition disclosed by the invention has the advantages that the weight of a mouse can be reduced by 12%-15%, the serum total cholesterol level and the leptin level are reduced, the number of fat cells per unit area is increased, the liver adiposis symptom is obviously improved, the expression of heat production factors in epididymal fat and groin fat is up-regulated, and liver toxicity is avoided. The raw materials of the composition for reducing fat and losing weight are all traditional Chinese medicines with homology of medicine and food, so that the composition has no obvious damage to organisms and is safer; the fat-reducing and weight-losing composition can achieve a good weight-losing effect by compounding the raw materials.

This invention discloses anti-leptin monoclonal antibodies and their applications, relating to the field of biotechnology. This invention develops anti-leptin monoclonal antibodies 2A122H7 and 6B62E3, which can effectively recognize leptin. The ELISA kits prepared using these monoclonal antibodies 2A122H7 and 6B62E3 include indirect ELISA and double-antibody sandwich ELISA kits, exhibiting high specificity and sensitivity for the tested samples, and are convenient, efficient, and cost-effective. This invention provides effective technical support for advancing research on the regulatory mechanisms of economic traits such as feed intake, fat deposition, and reproduction in poultry.

Methods for altering leptin resistance and the hormonal control of energy balance, and methods for treating obesity and diabetes, as well as promoting weight gain, using batotin and batotin inhibitors.

The invention provides a breast cancer risk assessment method which is suitable for BI-RADS compact type high-risk groups with BMI greater than or equal to 28 and estrogen greater than 50pg / mL, and the method comprises the following steps: S100, injecting a temperature-sensitive nano contrast agent which is matched with fat acoustic impedance at 37 DEG C and has tumor environment impedance mutation at 39-42 DEG C; s200, dynamically adjusting the voltage of the molybdenum target tube according to the BMI and filtering by adopting a 40keV energy spectrum; s300, based on the leptin / adiponectin ratio L, the estrogen E and the focus area A, calculating a risk score according to R = 0.7 L + 0.3 E * (1 + 50A); according to the scheme, through high-risk group limitation, temperature-sensitive contrast enhanced ultrasonic specificity, BMI self-adaptive molybdenum target penetration and a multi-parameter fusion model, the detection precision is remarkably improved, the microfocus detection sensitivity reaches 92.3%, and the specificity reaches 88.7%.

This application discloses the application of pyridostigmine in the preparation of drugs for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Validation was conducted using animal models of NAFLD induced by three different etiologies: methionine-choline deficiency diet, high-fat diet, and leptin gene knockout. Pyridostigmine significantly improved vagal nerve activity in the model animals (e.g., improving high-frequency and baroreflex sensitivity in heart rate variability), effectively corrected serum lipid metabolism disorders (reducing LDL cholesterol), alleviated hepatocyte damage (reducing ALT and AST), and at the histopathological level, reduced hepatic steatosis, decreased inflammatory cell infiltration, and inhibited collagen deposition, thereby achieving the prevention and treatment of NAFLD.

The present invention relates to antisense oligonucleotides (ASO) for use in treating, preventing, or ameliorating the progression of conditions such as type 2 diabetes mellitus (T2DM) and insulin resistance, leptin resistance, and obesity, Rater Syndrome, and cancer. Specifically, a thiomorpholino-containing ASO targets a protein tyrosine phosphatase non-receptor type 1 (PTPN1) gene transcript and induces exon skipping (including exon 2) of the transcript during RNA processing, thereby inhibiting expression of the protein tyrosine phosphatase-1B (PTP1B) protein.

Provided are compositions comprising leptin and methods of using the same to support weight loss. Also provided are modified leptins, including recombinant leptins, and methods of making and using the same.

The invention relates to the technical field of traditional Chinese medicine extracts, in particular to application of a codonopsis pilosula aqueous extract in preparation of a product for relieving or treating food-borne obesity. It is found for the first time through experimental research that the codonopsis pilosula aqueous extract can effectively improve the leptin level in hypothalamus of a food-borne obese mouse, inhibit expression of neurons NPY / Agrp for promoting ingestion and relieve central leptin resistance, so that appetite is reduced, food intake is reduced, then body weight is reduced, lipid deposition in the liver is reduced, and the weight of the mouse is reduced. Therefore, the composition can be used for preparing products for relieving or treating the food-borne obesity, such as functional foods beneficial to controlling fat in a body or medicines for treating the food-borne obesity or relieving symptoms of the food-borne obesity. The composition can be used for preparing the products for relieving or treating the food-borne obesity, such as the functional foods beneficial to controlling fat in the body or the medicines for treating the food-borne obesity or relieving symptoms of the food-borne obesity.

The invention discloses an anti-leptin monoclonal antibody and application thereof, and relates to the technical field of biology. According to the present invention, the anti-leptin monoclonal antibodies 2A122H7 and 6B62E3 are developed, and the leptin can be effectively identified; the ELISA kit prepared by using the monoclonal antibody 2A122H7 and 6B62E3 comprises an indirect ELISA kit and a double-antibody sandwich ELISA kit, and has the advantages of strong specificity and high sensitivity on a detection sample, convenient and efficient detection operation and low cost. Effective technical support is provided for research on regulation and control mechanisms of economic characters such as fowl ingestion, fat deposition and reproduction.

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

This invention belongs to the field of biomedical technology and discloses a specific structural lipase inhibitor that promotes ATGL activation, its preparation method, and its application. The inhibitor is derived from grape leaves. Through optimized extraction processes, the lipase inhibitory activity is significantly improved. The compound composition and structural ratio of the inhibitor are directionally enriched and clarified, resulting in a product with stable activity and controllable quality. Experiments have confirmed that the lipase inhibitor described in this application can simultaneously inhibit fat absorption and activate ATGL, forming a dual mechanism of action of "inhibiting absorption" and "inhibiting storage." It reduces TG, TC, LDL-C, LP, and FFA, upregulates HDL-C, stabilizes leptin, reduces ghrelin, and increases CCK and PYY, thereby effectively regulating lipid metabolism, controlling weight, improving blood lipids, and stabilizing blood sugar, with high safety.

Provided herein are leptin protein variants comprising cysteine substitutions. Also provided herein are methods of producing and using the leptin protein variants.

The present application discloses the use of Gastrodia extract in the preparation of products for promoting the secretion of adiponectin and / or inhibiting the secretion of leptin. A large number of experiments have confirmed that by using Gastrodia extract, the secretion of leptin is successfully inhibited, the secretion of adiponectin is promoted, and the ratio of leptin to adiponectin is reduced, showing the potential application value of Gastrodia extract in improving fat aging.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

The invention provides a plant extract compound for providing satiety. The plant extract compound is prepared from the following components in parts by weight: 1 part of lemon verbena extract, 0.5-2 parts of gymnema latifolium extract and 0.5-2 parts of roselle extract. The plant extract compound is prepared from the following components in parts by weight: 1 part of lemon verbena extract, 0.5-2 parts of gymnema latifolium extract and 0.5-2 parts of roselle extract. The satiety plant extract compound provided by the invention can significantly reduce the total cholesterol and LDL cholesterol level, improve the HDL cholesterol level and reduce the food intake through the bioactive components which influence the appetite regulation peptide level secreted by in-vivo fat tissues or digestive tracts, help to reduce appetite intake and promote the idea of health and weight loss, so that the total cholesterol and LDL cholesterol level can be significantly reduced, the HDL cholesterol level can be improved, and the food intake can be reduced. Reducing the blood glucose level and reducing the expression of leptin hormone, thereby reversing the overexpression of leptin and possibly eliminating resistance to leptin; accumulation of triglyceride in 3T3-L1 fat cells can be reduced, and cytoplasm AMPK can be activated; appetite can be reduced or satiety can be increased by affecting the level of peptides secreted by the digestive tract and adipose tissue.

The invention discloses a composition helpful for controlling in-vivo fat and application thereof, and relates to the technical field of biology. The hesperidin composition is prepared from hesperidin and lactobacillus johnsonii (Lactobacillus johnsonii), and the hesperidin composition is prepared from the hesperidin and the lactobacillus johnsonii. Research finds that the composition can achieve synergistic up-regulation of gene and protein expression of adipose tissue PGC1alpha and UCP1 and increase the body surface temperature; the composition can also significantly improve the bioavailability of hesperidin and improve the concentration of hesperetin and other metabolites in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the lactobacillus colonization rate, enrich the abundance of beneficial bacteria and promote the generation of short-chain fatty acids; the composition can also significantly improve lipid metabolism disorder of an organism, reduce fat accumulation, regulate adiponectin and leptin levels, control fat in the body and realize effective weight loss management.

Provided are compositions comprising leptin and methods of using the same to support weight loss. Also provided are modified leptins, including recombinant leptins, and methods of making and using the same.

Provided here are compositions for delivery of leptin to a cell. The compositions can comprise a proteo-lipid vehicle comprising a recombinant fusion-associated small transmembrane (FAST) polypeptide and a nucleic acid encoding leptin or a functional fragment thereof. Also provided are methods for using the compositions.